Structure

InChI Key BXZVVICBKDXVGW-NKWVEPMBSA-N
Smile O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1
InChI
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C10H12N4O3
Molecular Weight 236.23
AlogP -0.21
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 2.0
Polar Surface Area 93.03
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 17.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Human immunodeficiency virus type 1 reverse transcriptase inhibitor DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- 5370-7150 - - -
Secreted protein
- - 44000 - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
AIDS-Related Complex 3 D000386 ClinicalTrials
Acquired Immunodeficiency Syndrome 3 D000163 ClinicalTrials
Tuberculosis 3 D014376 ClinicalTrials
AIDS Dementia Complex 2 D015526 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Gastrointestinal disorders Diarrhoea 28.0
Gastrointestinal disorders Diarrhoea 21.0
Nervous system disorders Neurological symptom 20.0
Nervous system disorders Neuropathy peripheral 20.0
Gastrointestinal disorders Diarrhoea 19.0
Nervous system disorders Neurological symptom 17.0
Nervous system disorders Neuropathy peripheral 17.0
Gastrointestinal disorders Diarrhoea 15.0
Nervous system disorders Neurological symptom 14.0
Nervous system disorders Neuropathy peripheral 14.0
Gastrointestinal disorders Abdominal pain 13.0
Gastrointestinal disorders Gastrointestinal pain 13.0
Nervous system disorders Neurological symptom 12.0
Nervous system disorders Neuropathy peripheral 12.0
Skin and subcutaneous tissue disorders Dermatitis 9.0
Skin and subcutaneous tissue disorders Pruritus 9.0
Skin and subcutaneous tissue disorders Rash 9.0
Gastrointestinal disorders Abdominal pain 8.0
Skin and subcutaneous tissue disorders Dermatitis 8.0
Gastrointestinal disorders Gastrointestinal pain 8.0
Skin and subcutaneous tissue disorders Pruritus 8.0
Skin and subcutaneous tissue disorders Rash 8.0
Gastrointestinal disorders Abdominal pain 7.0
Skin and subcutaneous tissue disorders Dermatitis 7.0
Gastrointestinal disorders Gastrointestinal pain 7.0
Gastrointestinal disorders Pancreatitis 7.0
Skin and subcutaneous tissue disorders Pruritus 7.0
Skin and subcutaneous tissue disorders Rash 7.0
Gastrointestinal disorders Pancreatitis 6.0
Skin and subcutaneous tissue disorders Dermatitis 5.0
Skin and subcutaneous tissue disorders Pruritus 5.0
Skin and subcutaneous tissue disorders Rash 5.0
Gastrointestinal disorders Pancreatitis 3.0
Gastrointestinal disorders Pancreatitis 2.0

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Pregnancy, puerperium and perinatal conditions
16.96
Injury, poisoning and procedural complications
10.37
Investigations
6.42
Hepatobiliary disorders
5.94
Vascular disorders
5.87
Nervous system disorders
5.08
Gastrointestinal disorders
4.92
Metabolism and nutrition disorders
4.76
Congenital, familial and genetic disorders
4.69
Blood and lymphatic system disorders
4.62
General disorders and administration site conditions
4.11
Eye disorders
3.6
Cardiac disorders
3.37
Infections and infestations
3.14
Musculoskeletal and connective tissue disorders
3.05
Renal and urinary disorders
2.84
Psychiatric disorders
2.24
Respiratory, thoracic and mediastinal disorders
2.01

Cross References

Resources Reference
CAS NUMBER 69655-05-6
ChEBI 490877
ChEMBL CHEMBL1460
DrugBank DB00900
DrugCentral 869
EPA CompTox DTXSID6022927
FDA SRS K3GDH6OH08
Human Metabolome Database HMDB0015037
Guide to Pharmacology 4833
KEGG C06953
PDB 2DI
PharmGKB PA449301
PubChem 135398739
SureChEMBL SCHEMBL3363
ZINC ZINC000013597823